文献速递肾移植肾小球疾病

C3肾小球病与原发性免疫复合物介导的膜增生性肾小球肾炎肾移植结局

Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
PubMed 文献 · Kidney Int Rep · 2024-10-15

7例复发,复发后28%移植肾丢失,无复发者仅11%丢失,复发是移植肾丢失主要原因。蛋白尿可能是复发早期标志物。

要点

  • C3G/IC-MPGN肾移植后复发常见,平均复发时间1.2年。
  • 复发者移植肾丢失率28%,显著高于无复发者的11%。
  • 新发或快速增加的蛋白尿是复发早期标志,早于eGFR下降。

核心结论

  • C3G和IC-MPGN患者肾移植后疾病复发是移植肾丢失的主要原因。
  • 蛋白尿可作为疾病复发的早期生物标志物,应考虑用于患者管理和临床试验终点。

研究设计与样本

  • 移植时平均年龄48±16岁,53%的器官来自活体捐献者,平均随访4.7年。

主要发现

  • 7例(4例C3G和3例IC-MPGN)出现疾病复发,平均复发时间1.2年。
  • 复发后28%丢失移植肾,而无复发者仅11%丢失。
  • 疾病复发是所有患者移植肾丢失的主要原因。
  • 随访期间14%的患者死亡。
  • 新发或快速增加的蛋白尿是复发的早期标志,先于eGFR显著下降。

临床怎么用

  • 肾移植后应密切监测蛋白尿,作为C3G/IC-MPGN复发的早期指标。
  • 对于出现新发或快速增加蛋白尿的患者,应警惕疾病复发并及时评估。

局限性

  • 复发事件数较少(7例),可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Approximately 50% of patients with C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) reach kidney failure 10 years after diagnosis. Because these patients are generally young, the majority will be listed for kidney transplantation (KTx). However, reported outcomes in patients transplanted for C3G and IC-MPGN are heterogeneous and conflicting, because they are mainly based on retrospective monocentric studies. We thus aimed to provide detailed multicenter data on these patients, taking advantage of the ongoing nationwide Swiss Transplant Cohort Study (STCS). METHODS: We analyzed patient and graft outcomes, including the risk of graft loss in relation to recurrence of glomerulopathy. RESULTS: Forty-one (10 C3G and 31 IC-MPGN) transplanted recipients were included with a mean age at transplantation of 48 ± 16 years. Living donors provided 53% of the organs. During a mean follow-up of 4.7 years, 7 patients (4 C3G and 3 IC-MPGN) presented disease recurrence with a mean time to recurrence of 1.2 years. New-onset or rapidly increasing proteinuria was an early marker of recurrence, preceding significant decline in estimated glomerular filtration rate (eGFR). Following recurrence, 28% lost their graft, compared to 11% of patients without recurrence. Disease recurrence was the primary cause of graft loss in all patients. Finally, 14% of patients died during follow-up. CONCLUSION: This study provides important insights into the epidemiology and outcome of patients with C3G and IC-MPGN and their grafts after KTx. The data also suggest that proteinuria may serve as an early biomarker of disease recurrence and should be considered in patient management as well as an endpoint in current clinical trials using novel complement modulators.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Halfon M, Taffé P, Bucher C, et al. Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Kidney Int Rep. 2024. PMID: 39810762. doi:10.1016/j.ekir.2024.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。